The BIO International Convention attracts 15,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. BIO brings together a wide spectrum of life science and application innovators, including drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.

Meet with the below Lumanity Consultsants:

  • Ed Saltzman, Head , Biotech Strategy
  • Ginger Johnson, PhD, President, BioConsulting
  • Jeffrey Bockman, PhD, Executive Vice President, BioConsulting, Head of Oncology
  • Beth Fordham-Meier, Vice President, Business Development, Head, Corporate & Partnering Strategy Practice, BioConsulting
  • Michael Rice, MS, MBA, Senior Vice President, BioConsulting, Head of Advanced Therapeutics and Rare Disease
  • David Lomb, PhD, Principal, Autoimmune and Inflammatory Disease Co-Lead

Panel Participation at BIO

Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking

June 13, 2022 @ 1:00PM

Moderated by: Jeffrey Bockman, PhD, Executive Vice President, BioConsulting, Head of Oncology


  • Eric Rowinsky, CMO Hummingbird
  • Mai-Britt Zocca, IO Biotech Founder and CEO
  • Rachael Lester, SVP BD Harpoon Therapeutics
  • Sharon Benzeno, Chief BD Officer, Adaptive Technologies


Pre-POC biotechs, including platform companies, are increasingly recognizing the importance of early, scientifically grounded but clinically and commercially informed thinking around what targets and/or indications to pursue, often in advance of initial signals in human clinical studies. Such rationally based analyses can provide robust credibility and defensibility not only for internal decision-making but also for external communication to prospective investors and partners. Such early proactive and provisional direction, supported by appropriate objective research outside the echo chamber of the company itself, can substantially strengthen the internal and external story (the “pitch”) and significantly help drive value. The panel of experienced industry executives and board members will share their experiences and lessons learned from the hot seat, and discuss key strategic considerations with potential to drive, or attrit, significant value.

Trends, Challenges and Opportunities of Epigenetic Therapeutics in Cancer

June 14, 2022 @ 3:00PM


In recent times, the epigenetic drug discovery field has made substantial progress. So far, inhibitors targeting three epigenetic targets have been approved, including the first epigenetic inhibitor for solid tumors, and a plethora of molecules are progressing in clinical trials. Challenges of toxicity are being addressed by creative dosing regimens and combination therapies to ascertain positive outcomes in various cancer indications. Patient stratification for addressing the right population are being approached with innovative biomarker discovery strategies. Substantial literature evidence presents opportunities for epigenetic therapies in diverse malignancies such as neuro endocrine cancer.

Conference Website

Contact us to meet during the conference